Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 15/20 | 0.50 |
| ▸ | CRBN | Q96SW2 | 15/20 | 0.50 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 2/20 | 0.34 |
| ▸ | EGFR | P00533 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30169212 | 0.98 | DDB1 (0.50) | DDB1CRBNIRAK4GSK3BEGFR | |
| SCHEMBL22526259 | 0.98 | DDB1 (0.50) | DDB1CRBNIRAK4GSK3BEGFR | |
| SCHEMBL22526604 | 0.97 | DDB1 (0.49) | DDB1CRBNIRAK4GSK3BEGFR | |
| SCHEMBL30169139 | 0.97 | DDB1 (0.49) | DDB1CRBNIRAK4GSK3BEGFR | |
| SCHEMBL30169448 | 0.97 | DDB1 (0.49) | DDB1CRBNIRAK4GSK3BEGFR | |
| SCHEMBL22526507 | 0.97 | DDB1 (0.49) | DDB1CRBNIRAK4GSK3BEGFR | |
| SCHEMBL30169357 | 0.97 | DDB1 (0.51) | DDB1CRBNIRAK4GSK3BEGFR | |
| SCHEMBL22525443 | 0.97 | DDB1 (0.51) | DDB1CRBNIRAK4GSK3BEGFR | |
| SCHEMBL22526410 | 0.97 | DDB1 (0.50) | DDB1CRBNIRAK4GSK3BEGFR | |
| SCHEMBL30169453 | 0.97 | DDB1 (0.50) | DDB1CRBNIRAK4GSK3BEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| WO-2020206424-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | STAT4, STAT1, STAT3 | DDB1 3993/4885CRBN 171/4885IRAK4 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.